These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Mrass P; Weninger W Immunol Rev; 2006 Oct; 213():195-212. PubMed ID: 16972905 [TBL] [Abstract][Full Text] [Related]
7. Immune deviation in relation to ocular immune privilege. Streilein JW; Ksander BR; Taylor AW J Immunol; 1997 Apr; 158(8):3557-60. PubMed ID: 9103414 [TBL] [Abstract][Full Text] [Related]
8. A privileged view of NKT cells and peripheral tolerance through the eye. Stein-Streilein J Ocul Immunol Inflamm; 2005; 13(2-3):111-7. PubMed ID: 16019670 [TBL] [Abstract][Full Text] [Related]
9. The testis in immune privilege. Fijak M; Meinhardt A Immunol Rev; 2006 Oct; 213():66-81. PubMed ID: 16972897 [TBL] [Abstract][Full Text] [Related]
11. Immune regulation and the eye. Stein-Streilein J Trends Immunol; 2008 Nov; 29(11):548-54. PubMed ID: 18838303 [TBL] [Abstract][Full Text] [Related]
12. Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments. Streilein JW Curr Opin Immunol; 1993 Jun; 5(3):428-32. PubMed ID: 8347303 [TBL] [Abstract][Full Text] [Related]
13. Immune privilege in the anterior chamber of the eye. Niederkorn JY Crit Rev Immunol; 2002; 22(1):13-46. PubMed ID: 12186187 [TBL] [Abstract][Full Text] [Related]
14. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines. Chen PW; Ksander BR Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019 [TBL] [Abstract][Full Text] [Related]
15. A vision of cell death: Fas ligand and immune privilege 10 years later. Ferguson TA; Griffith TS Immunol Rev; 2006 Oct; 213():228-38. PubMed ID: 16972907 [TBL] [Abstract][Full Text] [Related]